Nevro Corp Stock News

Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Nevro Corp.'s (NVRO) CEO Keith Grossman on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Nevro Corp (NVRO) shares closed today at 1.3% above its 52 week low of $60.65, giving the company a market cap of $2B. The stock is currently down 21.5% year-to-date, down 62.3% over the past 12 months, and down 31.5% over the past five years. This week, the Dow Jones Industrial Average rose 4.3%, and the S&P 500 rose 5.5%. Trading Activity Trading volume this week was 56.6% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 88.2% The company's stock price performance over the past 12 months lags the peer average by 3911.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Nevro Corp (NVRO) shares closed this week 27.8% lower than it did at the end of last week. The stock is currently down 22.6% year-to-date, down 62.9% over the past 12 months, and down 25.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $87.71 and as low as $62.43 this week.Shares closed 66.4% below its 52-week high and 1.1% below its 52-week low.Trading volume this week was 36.7% lower than the 10-day average and 15.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 27.4% The company's stock price performance over the past 12 months lags the peer average by 880.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nevro Corp (NVRO) shares closed 1.1% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 22.6% year-to-date, down 62.9% over the past 12 months, and down 25.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Trading volume this week was 15.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 27.4% The company's stock price performance over the past 12 months lags the peer average by 880.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nevro Corp (NVRO) shares closed 2.5% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently down 14.2% year-to-date, down 60.5% over the past 12 months, and down 19.0% over the past five years. This week, the Dow Jones Industrial Average fell 3.0%, and the S&P 500 fell 4.8%. Trading Activity Trading volume this week was 107.9% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -5.4% The company's stock price performance over the past 12 months lags the peer average by 671.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Following a decline of more than 16% on Monday, Nevro <> continues to trade lower after its management responded to the FDAs approval of Medtronics (MDT) spinal cord

Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.